Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Cemiplimab
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Regeneron Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Medison Pharma Partners with Regeneron to Commercialize Libtayo® Globally
Details : Medison will commercialize Libtayo (cemiplimab), an anti-PD-1 monoclonal antibody, in select European and global markets under a new agreement.
Product Name : Libtayo
Product Type : Antibody
Upfront Cash : Undisclosed
August 01, 2024
Lead Product(s) : Cemiplimab
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Regeneron Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Patisiran
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Alnylam Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Medison and Alnylam Expand RNAi Therapeutics Partnership in Europe, Israel, and LATAM/APAC
Details : Alnylam's collaboration with Medison leverages Medison’s multi-regional platform to make RNAi therapeutics like ONPATTRO, GIVLAARI, and OXLUMO available in LATAM, APAC, and additional global markets.
Product Name : Onpattro
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
April 30, 2024
Lead Product(s) : Patisiran
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Alnylam Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Givosiran Sodium
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Alnylam Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Details : The new agreement will allow Alnylam to utilize Medison's unique multi-regional platform to ensure that Alnylam's innovative RNAi therapeutics, such as ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran) are made available across additiona...
Product Name : Givlaari
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
September 03, 2023
Lead Product(s) : Givosiran Sodium
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Alnylam Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Lead Product(s) : Odevixibat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Approved FDF
Sponsor : Albireo Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Details : Under the agreement with Albireo, Medison aims to commercialize Odevixibat in Canada and Israel, for the treatment of patients with cholestatic liver diseases. Odevixibat is approved in Europe as Bylvay® for the treatment of progressive familial intrahe...
Product Name : Bylvay
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 16, 2022
Lead Product(s) : Odevixibat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Approved FDF
Sponsor : Albireo Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Tebentafusp
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Immunocore
Deal Size : Undisclosed
Deal Type : Agreement
Details : The multi-territorial agreement to help seek regulatory authorization and commercialize Immunocore's KIMMTRAK® (tebentafusp -tebn) for the treatment of unresectable or metastatic uveal melanoma, a rare and aggressive form of melanoma that affects the ey...
Product Name : Kimmtrak
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
May 23, 2022
Lead Product(s) : Tebentafusp
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Immunocore
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Metreleptin
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Amryt Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Amryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada
Details : This agreement completes the multi-regional distribution agreements with Medison, announced in February, to distribute Myalept® (metreleptin) and Lojuxta® (lomitapide) in Israel, and Juxtapid® (lomitapide) in Canada.
Product Name : Myalepta
Product Type : Hormone
Upfront Cash : Undisclosed
August 03, 2021
Lead Product(s) : Metreleptin
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Amryt Pharma
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Ripretinib
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Deciphera Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Details : Deciphera Pharmaceuticals will distribution and commercialize QINLOCK, a switch-control tyrosine kinase inhibitor, in Canada and Israel for the treatment of fourth-line gastrointestinal stromal tumor (GIST).
Product Name : Qinlock
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 11, 2020
Lead Product(s) : Ripretinib
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Deciphera Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Zanubrutinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : BeiGene
Deal Size : Undisclosed
Deal Type : Agreement
Details : Medison will commercialize BeiGene’s BTK inhibitor BRUKINSA™ (zanubrutinib) in Israel and the acceptance of a new drug application (NDA) in Israel for BRUKINSA for the treatment of patients with mantle cell lymphoma (MCL) who have received at least o...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 21, 2020
Lead Product(s) : Zanubrutinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : BeiGene
Deal Size : Undisclosed
Deal Type : Agreement